Scientists hunt for clue to stop chemo from hurting hearts
NCT ID NCT06443645
Summary
This study aims to understand why some breast cancer patients develop heart damage from a common chemotherapy drug called anthracycline. Researchers will test if a specific protein in the blood (SGLT2) can serve as an early warning sign for this heart risk. The goal is to find a way to identify at-risk patients before damage occurs, so doctors can better protect their hearts during cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre Paul Strauss
RECRUITINGStrasbourg, France
Contact Email: •••••@•••••
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.